Drug therapy after heart infarction [Medikamentöse therapie nach herzinfarkt]

[1] Rouleau J.L., De Champlain J., Klein M., Et al., Activation of neurohumoral systems in postinfarction left ventricular dysfunction, J Am Coll Cardiol, 22, pp. 390-398, (1993)

[2] Pfeffer M.A., Iamas G.A., Vaughan D.E., Et al., Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction, N Engl J Med, 319, pp. 80-86, (1988)

[3] Pfeffer M.A., Braunwald E., Moye L.A., Et al., Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial, N Engl J Med, 327, pp. 669-677, (1992)

[4] Myocardial infarcton redefined - A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction, Eur Heart J, 21, pp. 1502-1513, (2000)

[5] Katus H.A., Remppis A., Neumann F.J., Et al., Diagnostic efficiency of troponin T measurements in acute myocardial infarction, Circulation, 83, pp. 902-912, (1991)

[6] Amman E.M., Tanasijevic M.J., Thompson B., Et al., Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes, N Engl J Med, 335, pp. 1342-1349, (1996)

[7] Empfehlungen zur Primär-und Sekundärprävention des ischämischen insults, Arzneiverordnung in Der Praxis, (1999)

[8] Gohlke H., Kubler W., Mathes P., Meinertz T., Schuler G., Gysan D.B., Sauer G., Empfehlungen zur umfassenden Risikoverminderung für Patienten mit koronarer Herzerkrankung, Gefäßerkrankungen und Diabetes, (2001)

[9] Wood D., De Backer G., Faergeman O., Graham I., Et al., Prevention of coronary heart disease in clinical practise. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention, J Hypertens, 16, pp. 1407-1414, (1998)

[10] Coronary heart disease: Reducing the risk. The scientific background for primary and secondary prevention of coronary heart disease. A worldwide view, Nutr Metab Cardiovasc Dis, 8, pp. 205-271, (1998)

[1] Rouleau J.L., De Champlain J., Klein M., Et al., Activation of neurohumoral systems in postinfarction left ventricular dysfunction, J Am Coll Cardiol, 22, pp. 390-398, (1993)

[2] Pfeffer M.A., Iamas G.A., Vaughan D.E., Et al., Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction, N Engl J Med, 319, pp. 80-86, (1988)

[3] Pfeffer M.A., Braunwald E., Moye L.A., Et al., Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial, N Engl J Med, 327, pp. 669-677, (1992)

[4] Myocardial infarcton redefined - A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction, Eur Heart J, 21, pp. 1502-1513, (2000)

[5] Katus H.A., Remppis A., Neumann F.J., Et al., Diagnostic efficiency of troponin T measurements in acute myocardial infarction, Circulation, 83, pp. 902-912, (1991)

[6] Amman E.M., Tanasijevic M.J., Thompson B., Et al., Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes, N Engl J Med, 335, pp. 1342-1349, (1996)

[7] Empfehlungen zur Primär-und Sekundärprävention des ischämischen insults, Arzneiverordnung in Der Praxis, (1999)

[8] Gohlke H., Kubler W., Mathes P., Meinertz T., Schuler G., Gysan D.B., Sauer G., Empfehlungen zur umfassenden Risikoverminderung für Patienten mit koronarer Herzerkrankung, Gefäßerkrankungen und Diabetes, (2001)

[9] Wood D., De Backer G., Faergeman O., Graham I., Et al., Prevention of coronary heart disease in clinical practise. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention, J Hypertens, 16, pp. 1407-1414, (1998)

[10] Coronary heart disease: Reducing the risk. The scientific background for primary and secondary prevention of coronary heart disease. A worldwide view, Nutr Metab Cardiovasc Dis, 8, pp. 205-271, (1998)